about
Bronchoscopy-guided antimicrobial therapy for cystic fibrosisInterventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosisAntibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosisOnce-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosisInterventions for the eradication of methicillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosisBronchoscopy-guided antimicrobial therapy for cystic fibrosisAntibiotic adjuvant therapy for pulmonary infection in cystic fibrosisReceiver operating characteristic curves for comparison of serial neutrophil band forms and C reactive protein in neonates at risk of infectionUS Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summaryUS Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosisA Glycopeptide Dendrimer Inhibitor of the Galactose-Specific Lectin LecA and of Pseudomonas aeruginosa BiofilmsExhaled breath hydrogen cyanide as a marker of early Pseudomonas aeruginosa infection in children with cystic fibrosisSide effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis.Rate of improvement of CF life expectancy exceeds that of general population--observational death registration study.Feasibility and pilot study of the effects of microfinance on mortality and nutrition in children under five amongst the very poor in India: study protocol for a cluster randomized controlled trial.Evaluating the effectiveness of a schools-based programme to promote exercise self-efficacy in children and young people with risk factors for obesity: steps to active kids (STAK).Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.Pneumonia due to viral and atypical organisms and their sequelae.Association between socioeconomic status, sex, and age at death from cystic fibrosis in England and Wales (1959 to 2008): cross sectional studyRisk factors for chronic kidney disease in adults with cystic fibrosis.Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis.Pseudomonas aeruginosa quorum sensing molecules correlate with clinical status in cystic fibrosisProphylactic antibiotics in cystic fibrosis: a conviction without evidence?Update on treatment of pulmonary exacerbations in cystic fibrosis.Clinical trials in cystic fibrosis.Environmental tobacco smoke and fetal health: systematic review and meta-analysis.Exacerbations in cystic fibrosis: 3--Management.The pharmacokinetics and toxicity of morning vs. evening tobramycin dosing for pulmonary exacerbations of cystic fibrosis: A randomised comparison.Perception of first respiratory infection with Pseudomonas aeruginosa by people with cystic fibrosis and those close to them: an online qualitative studyAminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity.Guideline on the design and conduct of cystic fibrosis clinical trials: the European Cystic Fibrosis Society-Clinical Trials Network (ECFS-CTN).Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: continuous or intermittent?Current dilemmas in antimicrobial therapy in cystic fibrosis.From pipeline to patient: new developments in cystic fibrosis therapeutics.Finding and filling the gaps in the evidence with high quality clinical trials - the experience of one Cochrane Review Group.Evidence into practice: how do we get past the roadblocks?European Cystic Fibrosis Society Standards of Care: Best Practice guidelines.Cystic fibrosis microbiology: Advances in antimicrobial therapy.Diagnostic and prognostic significance of systemic alkyl quinolones for P. aeruginosa in cystic fibrosis: A longitudinal study.Addressing resistance to antibiotics in systematic reviews of antibiotic interventions.
P50
Q24186413-0A1D65CD-B4A6-4D80-9402-E3E085EC8571Q24187987-ACD9210A-C171-479F-81A3-E497F0E7F61AQ24188054-0E55FBF9-09C6-4014-8B47-F6BF3A71ADF4Q24200604-0D9FD22B-F35D-46BF-9158-B3459EA7F687Q24200822-5AB18482-2B05-4DFB-B4E6-D39A901FC8CAQ24201620-5F229287-21E8-4FC3-9F07-F1737FB83184Q24202222-AA05D5F4-7AF7-4DBC-9AD6-0EC643865347Q24672541-88B1D3D6-2D79-4AFC-9A5C-BD087CE41049Q26775045-C142AA8A-A15A-438E-83C2-1C74C6633C76Q26775974-A107A819-56F4-4156-AC64-565B870E8AB1Q27673963-1F0101AC-BE9E-45FC-B243-9E0D299305D6Q28596799-E9A95B89-3621-4EF9-8EF2-7830DAAB5AA9Q30479961-8E2D9C2B-BEEA-4BA4-BFE5-3B4E8D0C6406Q33818393-747434B0-E69B-41AE-A5A1-CA6106B2AFD4Q33990537-D37980BF-1979-4174-A8F4-B626BDAE9C7DQ34059025-C76D8AE3-6C00-40DC-A7A2-D519B66A7031Q34098657-88FF09E9-DCAA-4715-BDDC-7D630ECF5E67Q34629015-2CB85997-10BB-4413-B751-B8266034B810Q35178544-3A5FFE45-80D6-4C43-B1B2-9DEBBBA91552Q35682983-6CC99256-92A3-443A-96ED-483FD37BB896Q36057093-B207FF0E-CDC7-4898-8109-A046E91FB33CQ36108849-FE1FEAF7-FC1C-44E7-A7F1-4EFCEEA01E59Q36275138-E8AC767C-A48F-44BA-8B1D-3BB43AC3FD29Q36629532-E3F2A8D1-6B71-45D1-BE21-287D995D8C1AQ36756922-9C179A18-754C-4E8C-A55F-71D430DB8C99Q37064690-87E0B180-CE87-4D0A-95A4-05A95E1232C5Q37072143-2FBA90C8-7BA4-4054-803D-CD552499370BQ37186935-54741198-7006-4A97-8B2F-4DAADE9D2CD2Q37576913-7DFBEF3B-B451-4350-8E92-00BBB928ED6BQ37784975-00C114AF-C64A-4E8D-BA36-7C6CEC8269F5Q37887190-68A3FCF5-E461-49DA-B1E7-93A92E5C1A26Q37972333-2EAE4454-F7A5-43CD-ACCE-FC34358CCD8CQ38042719-ACDE785E-7830-4B4A-B2C6-D3C956CDF5AAQ38078451-DEB78C4F-1A48-4AF9-A55F-C7789B4D4F60Q38170166-33D65AFC-34D2-4654-96A0-E7ACB0D78CF2Q38173144-5E273930-AA7D-42BA-8E59-3EBFB9BA5242Q38214213-B66E293A-F470-4377-A93C-83D99E95BBD0Q38367432-31940982-7497-40C3-9404-EBE28F2F013AQ38806946-639F5B6B-FAAC-4AAB-A5FE-D4AFBB76D807Q38832362-73CB36A9-63D4-4EF6-8894-A56B3AE3740D
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Alan R. Smyth
@ast
Alan R. Smyth
@en
Alan R. Smyth
@es
type
label
Alan R. Smyth
@ast
Alan R. Smyth
@en
Alan R. Smyth
@es
prefLabel
Alan R. Smyth
@ast
Alan R. Smyth
@en
Alan R. Smyth
@es
P106
P1153
7103344712
P21
P31
P496
0000-0001-5494-5438